alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.12


                                The Great Atlantic & Pacific Tea Company, Inc.
                                                               2 Paragon Drive
                                                    Montvale, New Jersey  07645

                                                           Christian W. E. Haub
                                                          Chairman of the Board
                                                        Chief Executive Officer



October 25, 2004


John Metzger
4205 Leslie Lane
Doylestown, PA  18901

Dear John:

This is to confirm our understanding that you will receive the company's SERP
benefit upon reaching age 55 (September 25, 2009) and still being employed in
the services of The Great Atlantic & Pacific Tea Co., Inc.

I am looking forward to your significant contributions to the company.

Sincerely,

/s/Christian Haub
-----------------
Christian Haub
Exhibit 10.70

                        AMENDMENT TO EMPLOYMENT AGREEMENT

THIS AMENDMENT TO EMPLOYMENT AGREEMENT (the "Amendment") dated March 14, 2003 is
entered into by and between Bactolac Pharmaceutical Inc., a Delaware corporation
(the "Company"), and Pailla Reddy (the "Executive").

                                    RECITALS

A. The Company and the Executive entered into an Employment Agreement dated
November 18, 2001 (the "Agreement"). B. The Parties have agreed to amend the
term of the Agreement.
                                    AGREEMENT

          NOW, THEREFORE, in consideration of the premises and the mutual
          promises set forth herein, the Company and the Executive hereby agree
          as follows:

1. 1. The first sentence of Section 1(a) is hereby amended to read in its
      entirety as follows:
     2.   Subject to the terms and conditions contained herein, the Company
          employs the Executive and the Executive accepts such employment from
          the date hereof until the earlier of (i) November 1, 2005 or (ii) the
          date such employment is terminated pursuant to Section 4 of this
          Agreement.

2.   Section 3(a) is hereby amended by the addition of the following sentences
     after the first sentence of Section 3(a):

<PAGE>
          The Executive's salary shall be reviewed no less frequently than
          annually by the Board with the first adjustment to the salary to occur
          on or about November 1, 2003. Any adjustments to the Executive's
          salary made by the Board shall be increases to the initial monthly
          salary of $20,833.33, and in determining any salary increases, the
          Board shall consider the Executive's performance for the Company as
          well as other factors the Board may consider relevant.

3.   Except as otherwise expressly provided herein, the Agreement, is not
     amended, modified or effected by this Amendment. Except as expressly set
     forth herein, all the terms, conditions, covenants, representations,
     warranties and all other provisions of the Agreement are hereby ratified
     and confirmed and shall remain in full force and effect.

4.   This Agreement may be executed in one or more counterparts, and it shall
     not be necessary that the signatures of all parties hereto be contained on
     any one counterpart hereof, each counterpart shall be deemed an original,
     and all of which together shall constitute one and the same instrument.


<PAGE>



IN WITNESS HEREOF, the Company and the Executive have executed this Amendment as
of the day and year first above written.
                                            BACTOLAC PHARMACEUTICAL INC.,
                                            a Delaware corporation


                                            By:
                                                 -------------------------------



                                            ------------------------------------
                                            Pailla Reddy, Individually





<PAGE>
### subpart 2—management of federal lands
|                 | /s/ Mark R. Baker                                                  |
|----------------------|--------------------------------------------------------------------|
| Date: March 15, 2012 | Mark R. BakerChief Executive Officer (Principal Executive Officer) |
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAY-31-2000
<PERIOD-START>                             JUN-01-1999
<PERIOD-END>                               AUG-31-1999
<CASH>                                         1781430
<SECURITIES>                                         0
<RECEIVABLES>                                 32084831
<ALLOWANCES>                                   4828655
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                        11368103
<DEPRECIATION>                                 5828010
<TOTAL-ASSETS>                                50333255
<CURRENT-LIABILITIES>                                0
<BONDS>                                       19484129
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                   27000000
<COMMON>                                         34762
<OTHER-SE>                                  (15907515)
<TOTAL-LIABILITY-AND-EQUITY>                  50333255
<SALES>                                              0
<TOTAL-REVENUES>                               8233249
<CGS>                                                0
<TOTAL-COSTS>                                7,798,948
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                             2,034,876
<INTEREST-EXPENSE>                           1,007,902
<INCOME-PRETAX>                              (2608477)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (2608477)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (2608477)
<EPS-BASIC>                                      (.09)
<EPS-DILUTED>                                    (.09)


</TABLE>
003 002

006

EH017

010

Snowdrift Road

Beaver

EH008

0516

0517a

050108

0516 0505

0516a

EH03

6

0517 0517

EH012 EH011

0514

EH010a

EH018

EH017

010

EH002

EH004

EH016

0517

119

EH005

050108

023

050108

021

024

022

113

EH010

17a

EH001

EH130

EH104

American Bar Road

Hauser Dam Rd

Creek R

Collins Drive

Ferry Drive

White Sandy

Recreation Site

Black SandyRecreation Site

Gates of the

Mountains Inc.

Upper Holter

Lake

Hauser Lake

Helena

National

Forest

Beacon

Hill

Range 3 West

Range 2 West

Township 12 North

Township 11 North

Range 3 West

Range 2 West

Township 13 NorthTownship 12 North

Range 4 West

Range 3 West

Township 13 NorthTownship 12 North

Range 4 West

Range 3 West

Township 12 North

Township 11 North

Winter road

closures may

be in effect

36 31

6 1

36

31

6

1

36 31

6 1

36 31

6

1

Rattlesnake

Mountain

HILGER

V A

LLEY

Stony

Point

Copper

Butte

M cLeod

Basin

Helena

National

Forest
[Federal Register Volume 76, Number 54 (Monday, March 21, 2011)]
[Notices]
[Pages 15349-15350]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-6637]


=======================================================================
-----------------------------------------------------------------------

NATIONAL SCIENCE FOUNDATION


National Science Board; Sunshine Act Meetings; Notice

    The National Science Board's Task Force on Data Policies (DP), 
pursuant to NSF regulations (45 CFR Part 614), the National Science 
Foundation Act, as amended (42 U.S.C. 1862n-5), and the Government in 
the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the 
scheduling of a workshop for the transaction of National Science Board 
business and other matters specified, as follows:

DATE, TIME AND SUBJECT MATTER: 

[[Page 15350]]

March 28, 2011

8:00 Welcome, Board Processes, and Participant Introductions
8:20-10 Session I: The Vision of Data-Intensive Science
10:15-12 Session II: Reproducibility, First Steps and Guiding 
Principles
12:30 High Performance Cyberinfrastructure is Needed to Enable Data-
Intensive Science and Engineering
1-3 Session III: Exemplars, Lessons Learned
3:15-5:30 Session IV: Impacts

March 29, 2011

8:30 National Science Foundation Perspective
8:45-10:30 Session V: Policy Issues
10:45-11 Public Comment Period
11-12:30 Session IV: Policy Issues (continued)
12:30 Adjourn

STATUS: Open.

LOCATION:  This workshop/meeting will be held at the National Science 
Foundation, 4201 Wilson Blvd., Room 1235, Arlington, VA 22230. All 
visitors must contact the Board Office [call 703-292-7000 or send an e-
mail message to <a href="/cdn-cgi/l/email-protection#0e606f7a6761606f627d6d676b606d6b6c7c6a4e607d6820696178"><span class="__cf_email__" data-cfemail="d2bcb3a6bbbdbcb3bea1b1bbb7bcb1b7b0a0b692bca1b4fcb5bda4">[email protected]</span></a>] at least 24 hours prior to 
the teleconference and provide name and organizational affiliation. All 
visitors must report to the NSF visitor desk located in the lobby at 
the 9th and N. Stuart Streets entrance on the day of the teleconference 
to receive a visitor's badge.

UPDATES & POINT OF CONTACT: Please refer to the National Science Board 
Web site http://www.nsf.gov/nsb for additional information and schedule 
updates (time, place, subject matter or status of meeting) may be found 
at http://www.nsf.gov/nsb/notices/. Point of contact for this meeting 
is: Blane Dahl, National Science Board Office, 4201 Wilson Blvd., 
Arlington, VA 22230. Telephone: (703) 292-7000.

Daniel A. Lauretano,
Counsel to the National Science Board.
[FR Doc. 2011-6637 Filed 3-17-11; 11:15 am]
BILLING CODE 7555-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[S. 913 Introduced in Senate (IS)]

<DOC>

116th CONGRESS
  1st Session
                                 S. 913

  To require group health plans and health insurance issuers offering 
health insurance coverage to disclose cost information to enrollees in 
                        such plans or coverage.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             March 27, 2019

   Mr. Braun introduced the following bill; which was read twice and 
  referred to the Committee on Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
  To require group health plans and health insurance issuers offering 
health insurance coverage to disclose cost information to enrollees in 
                        such plans or coverage.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``True Price Act''.

SEC. 2. REQUIREMENT TO DISCLOSE COSTS OF HEALTH CARE SERVICES.

    (a) In General.--Subpart II of part A of title XXVII of the Public 
Health Service Act (42 U.S.C. 300gg-11 et seq.) is amended by adding at 
the end the following:

``SEC. 2729A. REQUIREMENT TO DISCLOSE COSTS OF HEALTH CARE SERVICES.

    ``A group health plan or a health insurance issuer offering group 
or individual health insurance coverage shall disclose to enrollees in 
the plan or coverage the negotiated rate for each health care service 
covered under the plan or coverage, including the amount paid by such 
plan or issuer and any cost-sharing amount charged to the enrollee. 
Each group health plan or health insurance issuer shall post the 
information required to be disclosed under this section on the internet 
website of the health plan or health insurance issuer, and shall 
provide a hard copy of such information to enrollees upon request.''.
    (b) Effective Date.--Section 2729A of the Public Health Service 
Act, as added by subsection (a), shall take effect on [January 1, 
2020].
                                 <all>
```
Date(s) of

invalid data Summary of reson invalidated 01/04/2005 02/15/2005 02/21/2005 02/27/2005 03/05/2005 03/29/2005 01/28/20051 sample invalidated due to under run 02/03/20051 sample invalidated due to over run

1 90 15 7 47 22.1 80 For Q1, less than 50% data complete, no substitution done

If substitution was done the value of 80 would be used. Average PM10 (ug/m^3) Max 24-

hour Sample 6 samples invalidated due issues with the weighing system / lab error Summary of Payson Q1 2005 Invalid data

2005 Summary Statistics - PM10 Standard Conditions

Quarter No. of Days in Quarter No. of Possible Samples No. of

Actual Samples % Data

Complete

ness24 0

2nd Highest Sample No. of

Actual Exceedan 2005 Summary Statistics - PM10 Standard Conditions
NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

2009-7056

RICHARD A. DANIELS,

Claimant-Appellant,

v.

ERIC K. SHINSEKI,

Secretary of Veterans Affairs,

Respondent-Appellee.

Appeal from the United States Court of Appeals for Veterans Claims in

07-1317, Judge William A. Moorman.

ON MOTION

Before LINN, Circuit Judge.

ORDER

The court treats Richard A. Daniels' untimely brief as a motion for an extension of

time to file his brief.

Upon consideration thereof,

IT IS ORDERED THAT:

The motion is granted. The Secretary of Veterans Affairs should calculate the

due date for his brief from the date of filing of this order.

FOR THE COURT

MAY -1 2009	

/s/ Jan Horbaly

Date

cc:	Richard A. Daniels

Kent Kiffner, Esq.

Jan Horbaly

Clerk U.S. eau

THE Filthier*

s17	

MAY = 1 2009

riORIIALY

CLERIf
EXHIBIT 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Quarterly  Report on Form 10-QSB of  Quotemedia.com,
Inc. (the "Company") for the quarterly  period ended June 30, 2002 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"),  I, R.
Keith  Guelpa,  Chief  Executive  Officer of the  Company,  certify,  to my best
knowledge and belief, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss.
906 of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully  complies with the  requirements  of Section 13(a) or
          15(d) of the  Securities  Exchange  Act of 1934 (15  U.S.C.  78m(a) or
          78o(d)); and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
          material respects,  the financial  condition and results of operations
          of the Company.

By: /s/ R. Keith Guelpa
    ------------------------------
    R. Keith Guelpa
    Chief Executive Officer
    August 9, 2002
Exhibit








July 23, 2014
MR. EDWARD ANDRLE
Dear Ed:
With reference to the Agreement of December 29, 2010, related to your expatriate assignment which started February 2011, we herewith confirm that the above mentioned assignment is extended from now and until February 2016. All relevant terms and conditions will remain in full force, including during the extension period, you will continue to be assigned to Sorin S.p.A. (hereinafter "the Company") while remaining at all times an employee of Sorin Group USA, Inc. Prior to the end of the extension period, we will reevaluate your assignment taking into account the Company's Expatriate Policy and business needs at such time.
Ed, we trust these terms and conditions meet with your expectations.  Please kindly sign this letter below accordingly.


_____________________________    ____________________________________
V.P., Human Resources, Worldwide    V.P., Human Resources, Corporate & USA
(Stephane Bessette)    (Shelby Peralta)
For acceptance:
___________________________________    ______________________
(Ed Andrle)    Date










	
			
	Sorin Group USA, Inc.
	Tel.:    303 425-5508
	http://www.sorin.com

	14401 W. 65th Way
	800 221-7943
	 

	Arvada, CO 80004-3599
	FAX:   303 467-6212
	 

	United States of America
<PAGE>   1

                                                                   EXHIBIT 10.15

                               AMENDMENT AGREEMENT



The Letter Agreement of June 3, 1998 between Antigenics L.L.C. and Sigma-Tau
Industrie Farmaceutiche Riunite S.p.A. is hereby amended as follows:

-ON PAGE 1, THE INITIAL SIX LINES:

"Gentlemen:

We refer to our recent discussions regarding a potential scientific and business
cooperation between Antigenics L.L.C. ("Antigenics") and Sigma-Tau Industrie
Farmaceutiche Riunite S.p.A. (the "Company") in Italy (the "Territory") with
regard to Antigenics' proprietary technology on the use of Heat Shock Proteins
("HSP") for the use of HSP to boost and modulate the immune system against
cancer (the "Technology")."

are deleted and replaced by the following:

"Gentlemen:

We refer to our recent discussions regarding a potential scientific and business
cooperation between Antigenics L.L.C. ("Antigenics") and Sigma-Tau Industrie
Farmaceutiche Riunite S.p.A. (the "Company") in Italy, Spain, Portugal and
Switzerland (the "Territory") with regard to Antigenics' proprietary technology
on the use of Heat Shock Proteins ("HSP") for the use of HSP to boost and
modulate the immune system against cancer (the "Technology")."

-ON PAGE 1, PARAGRAPH 2, 10TH LINE:

"by the Company, within 12 (twelve) months from the date of this Letter
Agreement; it being"

is deleted and replaced by the following:

"by the Company, within 30 (thirty) months from the date of this Letter
Agreement; it being"

-ON PAGE 1, PARAGRAPH 3., 3RD LINE:

"parties, (ii) six months from the completion of the second Trial, if the
parties agree to only"

is deleted and replaced by the following:

"PARTIES, (ii) TWELVE MONTHS FROM THE COMPLETION OF THE SECOND TRIAL, IF THE
PARTIES AGREE TO ONLY"




<PAGE>   2


IN WITNESS WHEREOF, the parties have executed this Amendment Agreement by their
duly authorized representatives in duplicate as of the day and year below
written.

ANTIGENICS, L.L.C.                      SIGMA-TAU INDUSTRIE
                                        FARMACEUTICHE
                                        RUINITE S.p.A.



By:  /s/ Garo Armen                     By:  /s/ Emilio Plate
     --------------------------------        --------------------------------


Name/Title:  Garo Armen                 Name/Title:  Emilio Plate - Chief
           --------------------------              --------------------------
                                                            Operating Officer


Date:  10/14/99                         Date:  20-10-99
     --------------------------------        --------------------------------
<TABLE> <S> <C>


<ARTICLE>                     9
<MULTIPLIER>                                         1,000

<S>                           <C>
<PERIOD-TYPE>                 3-MOS
<FISCAL-YEAR-END>                              JUN-30-2000
<PERIOD-END>                                   SEP-30-1999
<CASH>                                               6,231
<INT-BEARING-DEPOSITS>                                 500
<FED-FUNDS-SOLD>                                     5,202
<TRADING-ASSETS>                                         0
<INVESTMENTS-HELD-FOR-SALE>                         77,786
<INVESTMENTS-CARRYING>                                   0
<INVESTMENTS-MARKET>                                     0
<LOANS>                                             87,299
<ALLOWANCE>                                            776
<TOTAL-ASSETS>                                     185,518
<DEPOSITS>                                         143,005
<SHORT-TERM>                                             0
<LIABILITIES-OTHER>                                  1,178
<LONG-TERM>                                         25,361
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                                17
<OTHER-SE>                                          15,957
<TOTAL-LIABILITIES-AND-EQUITY>                     185,518
<INTEREST-LOAN>                                      1,758
<INTEREST-INVEST>                                    1,242
<INTEREST-OTHER>                                        73
<INTEREST-TOTAL>                                     3,073
<INTEREST-DEPOSIT>                                   1,159
<INTEREST-EXPENSE>                                   1,470
<INTEREST-INCOME-NET>                                1,603
<LOAN-LOSSES>                                           45
<SECURITIES-GAINS>                                      19
<EXPENSE-OTHER>                                      1,505
<INCOME-PRETAX>                                        268
<INCOME-PRE-EXTRAORDINARY>                             268
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                           168
<EPS-BASIC>                                         0.10
<EPS-DILUTED>                                         0.10
<YIELD-ACTUAL>                                        7.43
<LOANS-NON>                                            731
<LOANS-PAST>                                            96
<LOANS-TROUBLED>                                         0
<LOANS-PROBLEM>                                          0
<ALLOWANCE-OPEN>                                       740
<CHARGE-OFFS>                                           11
<RECOVERIES>                                             2
<ALLOWANCE-CLOSE>                                      776
<ALLOWANCE-DOMESTIC>                                   721
<ALLOWANCE-FOREIGN>                                      0
<ALLOWANCE-UNALLOCATED>                                 55



</TABLE>
EXHIBIT 32



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350



AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the quarterly report of NMXS.com, Inc. (the "Company") on Form 10-QSB for the quarter ended March 31, 2005, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned principal executive officer and the principal financial officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:  October
18, 2005







/s/ Richard Govatski

Richard Govatski, President

(Principal Executive Officer)







/s/ Teresa Dickey

Teresa Dickey, Treasurer

(Principal Financial Officer)